Target intelligence / Profile preview

Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta (PIK3CB)

Target
PIK3CB
Molecular classification
Enzyme, Kinase, Transferase, Phosphoinositide 3-kinase
01

Overview

Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta (PI3K p110beta), encoded by the PIK3CB gene, is a class IA phosphoinositide 3-kinase catalytic isoform that plays a critical role in cellular signaling, growth, survival, and metabolism. Unlike other class IA isoforms like p110alpha, which are primarily activated by receptor tyrosine kinases, p110beta is uniquely activated by both receptor tyrosine kinases and G-protein coupled receptors (GPCRs). It is also highly involved in platelet activation and aggregation, making it a key player in thrombosis.

In oncology, PI3K p110beta has emerged as a major therapeutic target, particularly in PTEN-deficient cancers (such as prostate, breast, and endometrial cancers), which exhibit a unique dependency on p110beta signaling rather than p110alpha. Therapeutic strategies targeting this molecule involve selective small-molecule inhibitors, such as GSK2636771 and AZD8186, which bind to the ATP-binding pocket of the enzyme to block downstream AKT pathway activation. However, clinical development of these inhibitors faces challenges, including safety concerns like hyperglycemia, gastrointestinal toxicities, and potential bleeding risks due to its physiological role in platelets.

Other names
Phosphatidylinositol 3-kinase catalytic subunit betaPhosphatidylinositol 3-kinase p110betaPI3-kinase subunit betaPI3K-betap110-betaPtdIns-3-kinase subunit betaPtdIns-3-kinase subunit p110-betaPIK3C1
02

Mechanism of action

Inhibition of the catalytic activity of the p110beta subunit of Class IA phosphoinositide 3-kinase (PI3K), preventing the phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-trisphosphate (PIP3). This blocks the recruitment and activation of downstream effectors such as AKT and PDK1, thereby inhibiting the PI3K/AKT/mTOR signaling pathway, which leads to decreased cell proliferation, survival, and platelet aggregation.

03

Biological functions

Signal transductionCell growthCell survivalCell proliferationPlatelet activationPlatelet aggregationAutophagyIntracellular signaling cascade
04

Disease associations

CancerThrombosisDiabetes
05

Safety considerations

HyperglycemiaGastrointestinal toxicitiesCutaneous reactionsIncreased risk of bleedingImmunosuppressionLiver toxicity
06

Interacting drugs

9 more in the full profile.

07

Biomarkers

PTEN lossPTEN mutationPTEN deletionPIK3CB gene amplificationPIK3CB mutationPhospho-AKT levels

Beyond the preview

Go deeper on Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta (PIK3CB).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta (PIK3CB).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call